Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer

Ji Soo Park, Jong Chan Youn, ChiYoung Shim, Geu Ru Hong, Choong Kun Lee, Jee Hyung Kim, Hyung Soon Park, Su Jin Heo, Seung Hoon Beom, Hyo Song Kim, SunYoung Rha, Hyuncheol Chung, seokmin kang, Minkyu Jung

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Trastuzumab-induced cardiotoxicity (TIC) is the primary adverse event that limits the use of trastuzumab in HER2-positive breast cancer patients. However, the incidence and risk factors of TIC in HER2-positive gastric cancer are not known. Therefore, we evaluated the incidence and predictive factors of TIC in gastric cancer patients treated with trastuzumab in clinical practice. We reviewed cardiac dysfunction in HER2-positive gastric cancer patients between December 2005 and April 2015 in a prospectively-collected database that included prospective clinical trials at Yonsei Cancer Center, Republic of Korea. TIC was defined as an absolute decline in left ventricular ejection fraction (LVEF) of at least 10 percentage points from the baseline to a value less than 55%, as identified by a multiple-gated acquisition scan or an echocardiogram. Among the 115 patients, 70 patients (60.9%) received trastuzumab combined with chemotherapy, and 45 patients (39.1%) received chemotherapy alone as a first-line therapy. Symptomatic heart failure was not observed in either group, but a significant asymptomatic drop in LVEF was noted in five (7.1%) of the trastuzumab combined-group patients and in one (2.2%) chemotherapy-only group patient [hazard ratio (HR), 3.47; 95% confidence interval (CI), 0.40-29.8; P=0.257]. TIC was observed more frequently in elderly patients than in younger patients (HR, per age in year, 1.16; 95% CI, 1.02-1.31; P=0.019). Similar to prior observations in breast cancer, TIC in gastric cancer patients is not frequent or reversible. However, the asymptomatic drop in LVEF should be monitored continually in HER2-positive gastric cancer patients treated with trastuzumab, especially in elderly patients.

Original languageEnglish
Pages (from-to)61837-61845
Number of pages9
JournalOncotarget
Volume8
Issue number37
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

Stomach Neoplasms
Stroke Volume
Drug Therapy
Cardiotoxicity
Trastuzumab
Confidence Intervals
Breast Neoplasms
Republic of Korea
Incidence
Heart Failure
Clinical Trials
Databases

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Park, J. S., Youn, J. C., Shim, C., Hong, G. R., Lee, C. K., Kim, J. H., ... Jung, M. (2017). Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Oncotarget, 8(37), 61837-61845. https://doi.org/10.18632/oncotarget.18700
Park, Ji Soo ; Youn, Jong Chan ; Shim, ChiYoung ; Hong, Geu Ru ; Lee, Choong Kun ; Kim, Jee Hyung ; Park, Hyung Soon ; Heo, Su Jin ; Beom, Seung Hoon ; Kim, Hyo Song ; Rha, SunYoung ; Chung, Hyuncheol ; kang, seokmin ; Jung, Minkyu. / Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. In: Oncotarget. 2017 ; Vol. 8, No. 37. pp. 61837-61845.
@article{e10589596a764b46b4981934bf35c96f,
title = "Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer",
abstract = "Trastuzumab-induced cardiotoxicity (TIC) is the primary adverse event that limits the use of trastuzumab in HER2-positive breast cancer patients. However, the incidence and risk factors of TIC in HER2-positive gastric cancer are not known. Therefore, we evaluated the incidence and predictive factors of TIC in gastric cancer patients treated with trastuzumab in clinical practice. We reviewed cardiac dysfunction in HER2-positive gastric cancer patients between December 2005 and April 2015 in a prospectively-collected database that included prospective clinical trials at Yonsei Cancer Center, Republic of Korea. TIC was defined as an absolute decline in left ventricular ejection fraction (LVEF) of at least 10 percentage points from the baseline to a value less than 55{\%}, as identified by a multiple-gated acquisition scan or an echocardiogram. Among the 115 patients, 70 patients (60.9{\%}) received trastuzumab combined with chemotherapy, and 45 patients (39.1{\%}) received chemotherapy alone as a first-line therapy. Symptomatic heart failure was not observed in either group, but a significant asymptomatic drop in LVEF was noted in five (7.1{\%}) of the trastuzumab combined-group patients and in one (2.2{\%}) chemotherapy-only group patient [hazard ratio (HR), 3.47; 95{\%} confidence interval (CI), 0.40-29.8; P=0.257]. TIC was observed more frequently in elderly patients than in younger patients (HR, per age in year, 1.16; 95{\%} CI, 1.02-1.31; P=0.019). Similar to prior observations in breast cancer, TIC in gastric cancer patients is not frequent or reversible. However, the asymptomatic drop in LVEF should be monitored continually in HER2-positive gastric cancer patients treated with trastuzumab, especially in elderly patients.",
author = "Park, {Ji Soo} and Youn, {Jong Chan} and ChiYoung Shim and Hong, {Geu Ru} and Lee, {Choong Kun} and Kim, {Jee Hyung} and Park, {Hyung Soon} and Heo, {Su Jin} and Beom, {Seung Hoon} and Kim, {Hyo Song} and SunYoung Rha and Hyuncheol Chung and seokmin kang and Minkyu Jung",
year = "2017",
month = "9",
day = "1",
doi = "10.18632/oncotarget.18700",
language = "English",
volume = "8",
pages = "61837--61845",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "37",

}

Park, JS, Youn, JC, Shim, C, Hong, GR, Lee, CK, Kim, JH, Park, HS, Heo, SJ, Beom, SH, Kim, HS, Rha, S, Chung, H, kang, S & Jung, M 2017, 'Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer', Oncotarget, vol. 8, no. 37, pp. 61837-61845. https://doi.org/10.18632/oncotarget.18700

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. / Park, Ji Soo; Youn, Jong Chan; Shim, ChiYoung; Hong, Geu Ru; Lee, Choong Kun; Kim, Jee Hyung; Park, Hyung Soon; Heo, Su Jin; Beom, Seung Hoon; Kim, Hyo Song; Rha, SunYoung; Chung, Hyuncheol; kang, seokmin; Jung, Minkyu.

In: Oncotarget, Vol. 8, No. 37, 01.09.2017, p. 61837-61845.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer

AU - Park, Ji Soo

AU - Youn, Jong Chan

AU - Shim, ChiYoung

AU - Hong, Geu Ru

AU - Lee, Choong Kun

AU - Kim, Jee Hyung

AU - Park, Hyung Soon

AU - Heo, Su Jin

AU - Beom, Seung Hoon

AU - Kim, Hyo Song

AU - Rha, SunYoung

AU - Chung, Hyuncheol

AU - kang, seokmin

AU - Jung, Minkyu

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Trastuzumab-induced cardiotoxicity (TIC) is the primary adverse event that limits the use of trastuzumab in HER2-positive breast cancer patients. However, the incidence and risk factors of TIC in HER2-positive gastric cancer are not known. Therefore, we evaluated the incidence and predictive factors of TIC in gastric cancer patients treated with trastuzumab in clinical practice. We reviewed cardiac dysfunction in HER2-positive gastric cancer patients between December 2005 and April 2015 in a prospectively-collected database that included prospective clinical trials at Yonsei Cancer Center, Republic of Korea. TIC was defined as an absolute decline in left ventricular ejection fraction (LVEF) of at least 10 percentage points from the baseline to a value less than 55%, as identified by a multiple-gated acquisition scan or an echocardiogram. Among the 115 patients, 70 patients (60.9%) received trastuzumab combined with chemotherapy, and 45 patients (39.1%) received chemotherapy alone as a first-line therapy. Symptomatic heart failure was not observed in either group, but a significant asymptomatic drop in LVEF was noted in five (7.1%) of the trastuzumab combined-group patients and in one (2.2%) chemotherapy-only group patient [hazard ratio (HR), 3.47; 95% confidence interval (CI), 0.40-29.8; P=0.257]. TIC was observed more frequently in elderly patients than in younger patients (HR, per age in year, 1.16; 95% CI, 1.02-1.31; P=0.019). Similar to prior observations in breast cancer, TIC in gastric cancer patients is not frequent or reversible. However, the asymptomatic drop in LVEF should be monitored continually in HER2-positive gastric cancer patients treated with trastuzumab, especially in elderly patients.

AB - Trastuzumab-induced cardiotoxicity (TIC) is the primary adverse event that limits the use of trastuzumab in HER2-positive breast cancer patients. However, the incidence and risk factors of TIC in HER2-positive gastric cancer are not known. Therefore, we evaluated the incidence and predictive factors of TIC in gastric cancer patients treated with trastuzumab in clinical practice. We reviewed cardiac dysfunction in HER2-positive gastric cancer patients between December 2005 and April 2015 in a prospectively-collected database that included prospective clinical trials at Yonsei Cancer Center, Republic of Korea. TIC was defined as an absolute decline in left ventricular ejection fraction (LVEF) of at least 10 percentage points from the baseline to a value less than 55%, as identified by a multiple-gated acquisition scan or an echocardiogram. Among the 115 patients, 70 patients (60.9%) received trastuzumab combined with chemotherapy, and 45 patients (39.1%) received chemotherapy alone as a first-line therapy. Symptomatic heart failure was not observed in either group, but a significant asymptomatic drop in LVEF was noted in five (7.1%) of the trastuzumab combined-group patients and in one (2.2%) chemotherapy-only group patient [hazard ratio (HR), 3.47; 95% confidence interval (CI), 0.40-29.8; P=0.257]. TIC was observed more frequently in elderly patients than in younger patients (HR, per age in year, 1.16; 95% CI, 1.02-1.31; P=0.019). Similar to prior observations in breast cancer, TIC in gastric cancer patients is not frequent or reversible. However, the asymptomatic drop in LVEF should be monitored continually in HER2-positive gastric cancer patients treated with trastuzumab, especially in elderly patients.

UR - http://www.scopus.com/inward/record.url?scp=85028755219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028755219&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18700

DO - 10.18632/oncotarget.18700

M3 - Article

VL - 8

SP - 61837

EP - 61845

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 37

ER -